Inform Go/No Go Drug Investment Decisions with Scientific Due Diligence/Asset Evaluation Partnering with emerging biopharma companies and acquiring drug product candidates is an essential part of the pharmaceutical business ecosystem. Emerging companies are focused on drug discovery and early development. They often lack the funding or experience to manage the complex, expensive, and time-consuming path […]
Read MoreDue Diligence/Asset Evaluation
0 comments.
Click here to read/write comments.
Topics: